• Watson Pharmaceuticals Inc., of Parsippany, N.J., said its subsidiary Watson Laboratories Inc. received approval from the FDA for its abbreviated new drug application for ibandronate 150-mg tablets, a generic equivalent to Boniva (Roche AG). It will ship the product beginning in the second quarter. There is a patent infringement lawsuit filed by Roche against Watson pending regarding ibandronate 150-mg tablets.